Theranosti Centre Srl®

«Neutronbrush[®]» device for **Neutron Intra-Operative** RadioTherapy (**nIORT**[®]): a new RT technique, performed during surgery (to remove tumours even at an advanced stage).



CNG for nIORT®



The "*Key* component" of NeutronBrush[®] device is a new **Compact Neutron Generator** (**CNG**). A collaboration agreement between ENEA and TheranostiCentre Srl (TC) was signed in 2019 and led to a **patent and to the manufacturing of TWO LABORATORY PROTOTYPES**, both built at Berkion Technology LLC (USA) and **installed** at **ENEA** Research Centre in Brasimone (BO).

The CNGs were designed for the **treatment of advanced solid tumours** with the **neutron Intra-Operative Radiation Therapy** (**nIORT**[®]). Fast neutrons (2.45 MeV energy) have a **radiobiological effectiveness** (**RBE**) \cong **3-5 times higher** than X-rays, γ -rays & electrons (used in current IORT techniques).











CNG patent

PCT/IT2021/000032 filed in July 2021 (WIPO/PCT Int. Public. in January 2023)

MULTI PURPOSE COMPACT APPARATUS FOR THE GENERATION OF A HIGH-FLUX OF NEUTRONS, PARTICULARLY FOR INTRAOPERATIVE RADIOTHERAPY

ABSTRACT

An apparatus (10, 100) for generating a high-flux of neutrons comprising a neutron generator (20, 120) which comprises an emission window (21, 121) and it is configured to emit, from said emission window (21, 121), a flow of neutrons (99), said neutron generator (20, 120) comprising a deuterium ion source chamber (40, 140) wherein positive deuterium ions (D+) or negative deuterium ions (D-) are generated, characterized in that said deuterium ions source chamber (40, 140) is provided with at least one exit electrode (50, 150) that is provided with at least one opening (51, 151) for the outward passage of at least some of said deuterium ions (D+, D-) from said deuterium ion source chamber (40, 140) in an axial direction (Y) towards said emission window (21, 121) through an acceleration tunnel (51,151);

wherein said neutron generator (20, 120) comprises a titanium target (14, 114) that is arranged at one end of said acceleration tunnel (51, 151), before said emission window (21, 121), and that is connected to a voltage generator (ΔV +, ΔV -) so as to be biased, said titanium target (14, 114) being configured to be struck by the deuterium ions (D+, D-) emitted from said deuterium ion source chamber (40, 140) and consequently to emit neutrons (99) from said emission window (21, 121); and wherein said acceleration tunnel (51, 151) extends along said axial direction (Y) from said at least one exit electrode (50, 150) to said titanium target (14, 114) and is defined by a lateral wall (27, 127) made of an electrical insulating material.





≥



PATENT COOPERATION TREATY

3



CNG design features

CNG is **compact** (~33cm | x 18 cm Ø) and **light** (<100 kg)

→ Remotely controllable with a robotic arm and usable in an operating room dedicated to nIORT[®]

CNG has 3 main components:

- 1) Plasma Source (D+ ions)
- 2) Accelerator column (High Density PE)
- 3) Titanium target (Ti)
- → Fusion DD reaction: **2.45 MeV neutrons**

CNG powered by 100 kV-10 mA DC:

- n yield = 3.3 10⁹ s⁻¹

- n flux ~10⁸ cm⁻² s⁻¹

10 ÷ 20 Gy (RBE) dose target (clinical end-point) in 8 ÷ 16 minutes (one-shot nIORT[®] treatment)







CNG prototypes



- Two CNG prototypes are currently located at the ENEA Research Centre in Brasimone. Accurate Radiation Protection calculations and Monte Carlo simulations are in progress to get authorizations (Category A)
- With LINCER project (2019-2022: "Laboratory for the characterization of Compact Neutron Irradiator in Emilia Romagna"), new bunker-laboratory @ ENEA equipped with instrumentation for neutron beam measurements
- Example: CNG + Anthropomorphic phantom







CNG with nIORT[®] applicator

Second CNG prototype (can be sealed):

- could be used in a hospital operating room without safety concerns

- will be equipped with an **IORT applicator** to be inserted into surgical cavity Monte Carlo analyses with MCNP code simulating potential nIORT[®] treatments demonstrate promising results e.g., nIORT[®] irradiation of breast and brain tumours (with craniotomy; GBM)

with hemispherical (iso-dose) and cylindrical (front-focused dose) applicators.





OPEN ACCESS

Published: March 31, 2023

RESEARCH ARTICLE

Theranosti Centre Srle

> A Compact Neutron Generator for the Niort® Treatment of Severe Solid Cancers

Maurizio Martellini ª^{.,} Massimo Sarotto ^ь, Ka-Ngo Leung ^с, Giuseppe Gherardi ª

 TheranostiCentre S.r.I., Via Freguglia 8 – 20122 Milan (ITALY)
 ENEA FSN-SICNUC-PSSN, C.R. Saluggia, Strada per Crescentino 41 – 13040 Saluggia (ITALY)
 Berkion Technology LLC, Colusa Avenue 1102 – 94707 Berkeley

(CA, USA)

* Scientific Director, Correspondence: <u>mmartellini1953@gmail.com</u>

ABSTRACT

In the last four years, TheranostiCentre S.r.I., Berkion Technology LLC and ENEA have patented and fabricated a first prototype of a Compact Neutron Generator (CNG) currently under testing in the ENEA laboratories. Besides the usual applications in the field of materials







Advantages by nIORT[®] 1/2

1) Direct irradiation of the tumor bed with 2.45 MeV monoenergetic neutrons:

- high linear energy transfer (LET ~30÷50 keV/mm)
- high radiobiological efficiency (RBE ~3-5 times than X & γ -rays and electrons)
- reduced oxygen enhancement ratio (OER)

→ high efficacy in tumour cells killing through DNA double breaks (DSBs)

- 2) Dose of neutron ionizing radiation is halved at 1 cm depth in irradiated tissues:
 reducing the risk of secondary radiation-induced tumours (RISMs)
 sparing nearby organs at risk (OARs) from radiogenic effects
- 3) Almost **isotropic spatial distribution of the radiation field** (as a sort of "ionizing foam" filling the surgical cavity):
 - killing of potential quiescent cancer microcells not removed by surgery;
 - risk reduction of developing, after the "one-shot" nIORT® treatment, cancer cells at the initial site, or in the form of local-regional metastases.
 Thanks to high-RBE neutrons, biochemical signals emitted by primary tumour cells to surrounding microcellular environment (TME) could be interrupted by fast neutrons,
 - → nIORT[®] treatment by Neutronbrush[®] could determine almost complete remission of solid tumour and local metastases in neighbouring TME (pre-clinical tests needed).





Advantages by nIORT[®] 2/2

4) Accurate MCNP calculations demonstrated the "**complementary**" **features** of nIORT[®] beam respect to standard IORT techniques e.g., focused LEX-IORT (50 keV X-rays) and IOERT (1 MeV electrons)

5) In clinical terms, nIORT[®] is a "neoadjuvant therapy" and could be subsequently accompanied by appropriate:

Theranosti Centre srl®

- chemotherapy (aimed at removing potential distant metastases)
- and/or immunotherapy (clinical evidence of synergistic effects*)
- → High-RBE neutrons should further enhance immune system response, stimulating both innate & adaptive immune responses in patients
- → More robust anti-tumour response by a multimodal approach protocol, potentially improving patient survival
- * Encouraging results by early-phase clinical trials exploiting **combinations** of **RT and immunotherapy**, including vaccines, ICIs & adoptive cell therapies







Journals and Patents

- Feasibility Study on the nIORT® Adjuvant Treatment of Brain and Breast Cancers by Fast Neutrons produced by a DD-fusion Compact Generator, M. Martellini, M. Sarotto, Ka-Ngo Leung, G. Gherardi, L. Falzone, American Journal of Biomedical Science & Research, [online] 22(3), May 2024, ISSN :2642-1747, DOI: <u>10.34297/AJBSR.2024.22.002969</u>
- Feasibility Study on the nIORT[®] Adjuvant Treatment of Glioblastoma Multiforme through the Irradiation Field of Fast Neutrons Produced by a Compact Generator, M. Martellini, M. Sarotto, Ka-Ngo Leung, G. Gherardi, A. Rizzo, G. Ottaviano, L. Falzone, European Society of Medicine, Journal Medical Research Archives, [online] 12(2), February 2024. <u>https://doi.org/10.18103/mra.v12i2.5090</u>
- A Compact Neutron Generator for the Niort[®] Treatment of Severe Solid Cancers, M. Martellini, M. Sarotto, Ka-Ngo Leung, G. Gherardi, European Society of Medicine, Journal Medical Research Archives, [online] 11(3), April 2023. <u>https://doi.org/10.18103/mra.v 11i3.379</u>
- Simulation of the nIORT[®] treatment by fast neutrons of severe brain cancers (as GBM) and comparison with standard IORT techniques adopting X-rays and electrons, M. Martellini, M. Sarotto, P. Ferrari, G. Gherardi, M. Venturi, In reviewing phase in Scivision Journal Cancer Science & Research [online]
- Multi Purpose Compact Apparatus for the Generation of a high-flux of neutrons, particularly for Intraoperative Radiotherapy, M. Martellini, G. Gherardi, K. Leung, J. Leung, M. Sarotto, A. Rizzo, July 5, 2021. Under evaluation at Patent Cooperation Treaty (PCT), International patent application n. PCT/IT2021/000032. World Intellectual Property Organization: International Publication n. WO 2023/281539 A1, January 2023.
- Apparatus for the intraoperative radiotherapy. Martellini M, Gherardi G. *European Patent* 2019; EP 3 522 177 B1.



State of the project

Two CNG prototypes – built by BT and purchased by TheranostiCentre Srl - are currently in a dedicated bunker at the ENEA Research Centre in Brasimone for **experimental characterisation**.

ENEA is partnering with TheranostiCentre Srl to perform **electromechanical tests** of the prototypes. **Plasma Ignition tests** (with Hydrogen) will begin as soon as ENEA has obtained the mandatory certifications.

In the meanwhile:

- TheranostiCentre Srl has researched a possible company in the field of generators for medical devices to proceed in **planning the path towards a TRL8**
- some interactions with private and public companies and entities have been undertaken to obtain the **necessary funds** and find **formula** to reach the determined **goal in the planned time**



Mission of TC and future steps

TheranostiCentre Srl is a company that:

- deals with R&D of technology related to the use of neutrons in equipment for the treatment of solid tumours
- does not have as its corporate purpose to become a production or distribution unit of the Neutronbrush® device.

First phase:

- Initial **experimental tests** will be carried out in the ENEA bunker-laboratory;
- Further **tests** will be carried out **in vivo and on organoids** with the support of technical/clinical personnel (also to analyse future steps oriented towards subsequent Neutronbrush[®] industrialization).

In the second phase:

- Neutronbrush[®] will be manufactured as a medical device suitable for use in an operating room with the support of IORT clinical personnel (in collaboration with hospitals and/or university clinics will be necessary)

In the third phase:

- TheranostiCentre Srl, the partner company and ENEA will work on the device insertion into an industrial chain, including the production of both the Neutronbrush[®] and the robotic arm for its movement (with related support equipment).

The fourth phase will be dedicated to analyse the reference market and the distribution of the finished product.

Certainly, in the development of the project, there will be phases of product and process patenting, certifications, etc.



Contatti: TheranostiCentre Srl Via Freguglia 8 20122 Milano

Direttore Scientifico: Prof. Maurizio Martellini <u>mmartellini1953@gmail.com</u>